Exchange: NASDAQ·Updated 04:28 AM EDT

HELP News

News
all
press releases
HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results
Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.
Stocktwits
HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results
Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.
Stocktwits
More News
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
Inspire Medical, Cybin and Aveanna show overbought RSI readings above 70, signaling potential momentum warnings for healthcare investors.read more...
Benzinga
HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62
TD Cowen lifted its target on HELP to $62 from $8 on Thursday, while maintaining a Buy rating.
Stocktwits
Helus Pharma Appoints Michael Halstead CEO, Effective Immediately
(RTTNews) - On Monday, Cybin D/B/A Helus Pharma (HELP) announced that it has appointed Michael Halstead as Chief Executive Officer, effective immediately...
Nasdaq News: Markets
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.
Stocktwits
HELP Stock Surges To Over 6-Month Highs Led By Crucial Phase 3 Milestone – Retail Expects It To Hit Fresh 52-Week Highs
Helus Pharma said it completed enrollment ahead of schedule in the Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder.
Stocktwits
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening PR Newswire NEW YORK and TORONTO, July 21, 2026 Issued on behalf of...
PR Newswire
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates PR Newswire NEW YORK, July 21, 2026 Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations...
PR Newswire
ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside
H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.
Stocktwits
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time PR Newswire NEW YORK, July 17, 2026 Issued on...
PR Newswire

Advertisement|Remove ads.